A decade of FRAX: how has it changed the management of osteoporosis?
暂无分享,去创建一个
J. Kanis | E. McCloskey | W. Leslie | M. Lorentzon | L. Vandenput | H. Johansson | N. Harvey | E. Liu
[1] T. Peters,et al. Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial , 2019, Osteoporosis International.
[2] C. Cooper,et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures , 2019, Osteoporosis International.
[3] J. Kanis,et al. Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study , 2019, Osteoporosis International.
[4] F. Rutters,et al. The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] J. Kanis,et al. Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry‐Based Cohort Study , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] J. Kanis,et al. The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease. , 2019, Kidney international.
[7] A. Grauer,et al. Risk of subsequent fracture after prior fracture among older women , 2018, Osteoporosis International.
[8] J. Kanis,et al. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] J. Kanis,et al. Characteristics of recurrent fractures , 2018, Osteoporosis International.
[10] R. Rizzoli,et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis , 2018, The Journal of clinical endocrinology and metabolism.
[11] C. Cooper,et al. The Cost‐Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] T. Peters,et al. Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures—A Post Hoc Analysis of the SCOOP Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] C. Cooper,et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial , 2017, The Lancet.
[14] P. Geusens,et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.
[15] C. Cooper,et al. Service level predictors of bone treatment recommendations after a fragility fracture: Baseline findings from the first UK patient level Fracture Liaison Service Audit , 2018 .
[16] J. Kanis,et al. FRAX-based intervention and assessment thresholds in seven Latin American countries , 2018, Osteoporosis International.
[17] M. Bech,et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study , 2018, Osteoporosis International.
[18] A. Grauer,et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.
[19] J. Kanis,et al. FRAX- vs. T-score-based intervention thresholds for osteoporosis , 2017, Osteoporosis International.
[20] Anders Odén,et al. Overview of Fracture Prediction Tools. , 2017, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[21] E. Skovlund,et al. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway , 2017, Osteoporosis International.
[22] C. Cooper,et al. UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.
[23] D. Dempster,et al. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] J. Kanis,et al. FRAX Update. , 2017, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[25] V. Gudnason,et al. Imminent risk of fracture after fracture , 2017, Osteoporosis International.
[26] C. Cooper,et al. A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.
[27] R. Neer,et al. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. , 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[28] J. Kanis,et al. Adjusting Hip Fracture Probability in Men and Women Using Hip Axis Length: the Manitoba Bone Density Database. , 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[29] Jacques P. Brown,et al. A Meta‐Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[30] G. Kyriakos,et al. Impact of the NOGG and NOF Guidelines on the Indication of Bone Mineral Density in Routine Clinical Practice. , 2015, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[31] J. Kanis,et al. Intervention Thresholds and the Diagnosis of Osteoporosis , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[32] J. Kanis,et al. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture , 2015, Osteoporosis International.
[33] J. Kanis,et al. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX , 2015, Osteoporosis International.
[34] C. Cooper,et al. FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK , 2015, Osteoporosis International.
[35] D. Mellström,et al. Is the Swedish FRAX model appropriate for Swedish immigrants? , 2015, Osteoporosis International.
[36] J. Kanis,et al. Adjusting Fracture Probability by Trabecular Bone Score , 2015, Calcified Tissue International.
[37] M. Cowie. National Institute for Health and Care Excellence. , 2015, European heart journal.
[38] J. Kanis,et al. Estimated Lean Mass and Fat Mass Differentially Affect Femoral Bone Density and Strength Index but Are Not FRAX Independent Risk Factors for Fracture , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[39] A. LaCroix,et al. Impact of Femoral Neck and Lumbar Spine BMD Discordances on FRAX Probabilities in Women: A Meta-analysis of International Cohorts , 2014, Calcified Tissue International.
[40] J. Kanis,et al. Lumbar spine texture enhances 10-year fracture probability assessment , 2014, Osteoporosis International.
[41] J. Cauley,et al. Geographic and ethnic disparities in osteoporotic fractures , 2014, Nature Reviews Endocrinology.
[42] C. Cooper,et al. Challenges for the Development of Bone-Forming Agents in Europe , 2014, Calcified Tissue International.
[43] C. Cooper,et al. Worldwide uptake of FRAX , 2014, Archives of Osteoporosis.
[44] E. M. Lewiecki,et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
[45] J. Kanis,et al. Incidence of Hip Fracture in Romania and the Development of a Romanian FRAX Model , 2013, Calcified Tissue International.
[46] J. Kanis,et al. FRAX provides robust fracture prediction regardless of socioeconomic status , 2013, Osteoporosis International.
[47] Naoto Endo,et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary , 2012, Archives of Osteoporosis.
[48] J. Kanis,et al. Type 2 diabetes and bone , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[49] J. Kanis,et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[50] J. Kanis,et al. Does osteoporosis therapy invalidate FRAX for fracture prediction? , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[51] Carol Coupland,et al. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study , 2012, BMJ : British Medical Journal.
[52] C. Cooper,et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis , 2012, Osteoporosis International.
[53] C. Cooper,et al. A systematic review of hip fracture incidence and probability of fracture worldwide , 2012, Osteoporosis International.
[54] J. Compston,et al. A comparison of case-finding strategies in the UK for the management of hip fractures , 2012, Osteoporosis International.
[55] R. Rizzoli,et al. Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland , 2012, Osteoporosis International.
[56] J. Kanis,et al. FRAX® with and without Bone Mineral Density , 2011, Calcified Tissue International.
[57] S. Boonen,et al. Official Positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[58] J. Kanis,et al. High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice , 2011, Osteoporosis International.
[59] W. Leslie,et al. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos , 2011, Osteoporosis International.
[60] J. Kanis,et al. Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement , 2011, Osteoporosis International.
[61] J. Kanis,et al. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX® , 2011, Osteoporosis International.
[62] J. Kanis,et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids , 2011, Osteoporosis International.
[63] Eugene McCloskey,et al. Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[64] J. Kanis,et al. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. , 2010, Bone.
[65] W. Leslie,et al. Time since prior fracture is a risk modifier for 10‐year osteoporotic fractures , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[66] Carol Coupland,et al. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores , 2009, BMJ : British Medical Journal.
[67] J. Kanis,et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. , 2009, Bone.
[68] O. Johnell,et al. BMD, clinical risk factors and their combination for hip fracture prevention , 2009, Osteoporosis International.
[69] C. Cooper,et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. , 2009, Maturitas.
[70] J. Kanis,et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study , 2009, Osteoporosis International.
[71] C. Cooper,et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.
[72] J. Kanis,et al. Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK , 2008, Osteoporosis International.
[73] B. Dawson-Hughes. A revised clinician's guide to the prevention and treatment of osteoporosis. , 2008, The Journal of clinical endocrinology and metabolism.
[74] N. D. Nguyen,et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks , 2008, Osteoporosis International.
[75] L. Melton,et al. A reference standard for the description of osteoporosis. , 2008, Bone.
[76] L. Melton,et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA , 2008, Osteoporosis International.
[77] C. Cooper,et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.
[78] C. Cooper,et al. The cost-effectiveness of alendronate in the management of osteoporosis. , 2008, Bone.
[79] L. Melton,et al. Cost-effective osteoporosis treatment thresholds: the United States perspective , 2008, Osteoporosis International.
[80] O. Johnell,et al. FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.
[81] G. Anderson,et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. , 2007, Journal of the National Cancer Institute.
[82] S. Jamal,et al. Low bone mineral density and fracture burden in postmenopausal women , 2007, Canadian Medical Association Journal.
[83] J Bamford,et al. Current practice, accuracy, effectiveness and cost-effectiveness of the school entry hearing screen. , 2007, Health technology assessment.
[84] Mark Stevenson,et al. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. , 2007, Health technology assessment.
[85] Jacques P. Brown,et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.
[86] O. Johnell,et al. The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry , 2005, Osteoporosis International.
[87] J. Kanis,et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.
[88] C. Cooper,et al. Guidelines for diagnosis and management of osteoporosis , 2005, Osteoporosis International.
[89] Niklas Zethraeus,et al. Assessment of fracture risk , 2005, Osteoporosis International.
[90] O. Johnell,et al. Optimization of BMD Measurements to Identify High Risk Groups for Treatment—A Test Analysis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[91] O. Johnell,et al. Fracture risk following an osteoporotic fracture , 2004, Osteoporosis International.
[92] O. Johnell,et al. Acute and Long-Term Increase in Fracture Risk after Hospitalization for Vertebral Fracture , 2001, Osteoporosis International.
[93] O. Johnell,et al. The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.
[94] O Johnell,et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. , 2000, Bone.
[95] N. Ghannam,et al. Book review: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. , 1994, Annals of Saudi medicine.